Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications - PubMed (original) (raw)
Review
. 1999:60 Suppl 2:27-39; discussion 40-1, 113-6.
Affiliations
- PMID: 10073385
Review
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications
H K Manji et al. J Clin Psychiatry. 1999.
Abstract
In an attempt to find the key to reducing the excessive morbidity and mortality seen with mood disorders, our laboratory has been extensively investigating lithium's mechanisms of action in an integrated series of clinical and preclinical studies. We have found that the chronic administration of the 2 structurally highly dissimilar agents, lithium and valproate, brings about a strikingly similar reduction in protein kinase C (PKC) alpha and epsilon isozymes in rat frontal cortex and hippocampus. In view of PKC's critical role in regulating neuronal excitability and neurotransmitter release, we have postulated that PKC inhibition may have antimanic efficacy. In a small study, we have found that tamoxifen (which, in addition to its estrogen receptor blockade, is also a PKC inhibitor) has marked antimanic efficacy. These exciting preliminary results suggest that PKC inhibitors may represent a novel class of improved therapeutic agents for bipolar disorder, and this is under further investigation. The beneficial effects of mood stabilizers require a lag period for onset of action and are generally not immediately reversed upon drug discontinuation; such patterns of effects suggest alterations at the genomic level. We have therefore undertaken a series of studies to investigate the effects of these agents on the AP-1 family of transcription factors and have found that both drugs increase AP-1 DNA binding activity in areas of rodent brain ex vivo and in human neuronal cells in culture. Both treatments also increase the expression of a reporter gene driven by an AP-1-containing promoter, and mutations in the AP-1 sites of the reporter gene promoter markedly attenuate these effects. Both treatments also increase the expression of several endogenous proteins, whose genes are known to be regulated by AP-1. Although the precise mechanisms have not been fully elucidated, preliminary results suggest that these effects may be mediated, in part, by mitogen-activating protein kinases and glycogen synthase kinase 3beta. We have also utilized mRNA reverse transcription-polymerase chain reaction (RT-PCR) differential display to identify concordant changes in gene expression induced by the chronic administration of both lithium and valproate. We have identified concordant changes in a number of cDNA bands by both lithium and valproate. Cloning and characterizing of these genes is currently underway. The identification of the functions of these genes offers the potential not only for improved therapeutics for reducing the morbidity and mortality associated with mood disorders, but may also provide important clues about the underlying pathophysiology.
Similar articles
- Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers.
Manji HK, Moore GJ, Chen G. Manji HK, et al. Br J Psychiatry Suppl. 2001 Jun;41:s107-19. Br J Psychiatry Suppl. 2001. PMID: 11450170 Review. - Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?
Lenox RH, McNamara RK, Watterson JM, Watson DG. Lenox RH, et al. J Clin Psychiatry. 1996;57 Suppl 13:23-31; discussion 32-3. J Clin Psychiatry. 1996. PMID: 8970502 - Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy.
Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI, Potter WZ. Manji HK, et al. J Clin Psychiatry. 1996;57 Suppl 13:34-46; discussion 47-8. J Clin Psychiatry. 1996. PMID: 8970503 Review. - The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
Gray NA, Zhou R, Du J, Moore GJ, Manji HK. Gray NA, et al. J Clin Psychiatry. 2003;64 Suppl 5:3-17. J Clin Psychiatry. 2003. PMID: 12720479 Review.
Cited by
- Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers.
Lee JG, Woo YS, Park SW, Seog DH, Seo MK, Bahk WM. Lee JG, et al. Clin Psychopharmacol Neurosci. 2022 May 31;20(2):228-239. doi: 10.9758/cpn.2022.20.2.228. Clin Psychopharmacol Neurosci. 2022. PMID: 35466094 Free PMC article. Review. - Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP.
Kalkman HO. Kalkman HO. Pharmaceuticals (Basel). 2019 Jul 29;12(3):113. doi: 10.3390/ph12030113. Pharmaceuticals (Basel). 2019. PMID: 31362361 Free PMC article. Review. - Valproic acid stimulates in vitro migration of the placenta-derived mesenchymal stem/stromal cell line CMSC29.
Al-Sowayan B, Keogh RJ, Abumaree M, Georgiou HM, Kalionis B. Al-Sowayan B, et al. Stem Cell Investig. 2019 Feb 13;6:3. doi: 10.21037/sci.2019.01.01. eCollection 2019. Stem Cell Investig. 2019. PMID: 30976600 Free PMC article. - Inositol depletion, GSK3 inhibition and bipolar disorder.
Yu W, Greenberg ML. Yu W, et al. Future Neurol. 2016 May;11(2):135-148. doi: 10.2217/fnl-2016-0003. Epub 2016 Apr 26. Future Neurol. 2016. PMID: 29339929 Free PMC article. Review. - Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents.
Fallah E, Arman S, Najafi M, Shayegh B. Fallah E, et al. Iran J Child Neurol. 2016 Spring;10(2):16-25. Iran J Child Neurol. 2016. PMID: 27247580 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical